Compare Novartis with S.A.ENTERPRISES - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NOVARTIS vs S.A.ENTERPRISES - Comparison Results

Rs 100 invested in...

Loading...
DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NOVARTIS S.A.ENTERPRISES NOVARTIS/
S.A.ENTERPRISES
 
P/E (TTM) x 81.4 -31.1 - View Chart
P/BV x 2.5 2.3 109.8% View Chart
Dividend Yield % 1.4 0.0 -  

Financials

 NOVARTIS   S.A.ENTERPRISES
EQUITY SHARE DATA
    NOVARTIS
Mar-21
S.A.ENTERPRISES
Mar-21
NOVARTIS/
S.A.ENTERPRISES
5-Yr Chart
Click to enlarge
High Rs77011 7,326.4%   
Low Rs5012 20,120.5%   
Sales per share (Unadj.) Rs154.51.8 8,751.0%  
Earnings per share (Unadj.) Rs8.5-0.3 -3,050.4%  
Cash flow per share (Unadj.) Rs13.4-0.1 -11,395.8%  
Dividends per share (Unadj.) Rs10.000-  
Avg Dividend yield %1.60-  
Book value per share (Unadj.) Rs289.217.7 1,630.5%  
Shares outstanding (eoy) m24.694.00 617.3%   
Bonus / Rights / Conversions ---  
Price / Sales ratio x4.13.7 111.8%   
Avg P/E ratio x75.1-23.5 -319.8%  
P/CF ratio (eoy) x47.5-55.3 -85.8%  
Price / Book Value ratio x2.20.4 599.7%  
Dividend payout %118.10-   
Avg Mkt Cap Rs m15,69126 60,350.0%   
No. of employees `000NANA-   
Total wages/salary Rs m1,0853 34,230.3%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m3,8147 54,015.6%  
Other income Rs m3324 9,458.7%   
Total revenues Rs m4,14611 39,219.5%   
Gross profit Rs m267-4 -6,555.3%  
Depreciation Rs m1221 19,000.0%   
Interest Rs m770 109,714.3%   
Profit before tax Rs m400-1 -31,777.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1910 -119,625.0%   
Profit after tax Rs m209-1 -18,828.8%  
Gross profit margin %7.0-57.6 -12.1%  
Effective tax rate %47.812.4 385.8%   
Net profit margin %5.5-15.7 -35.0%  
BALANCE SHEET DATA
Current assets Rs m9,22458 15,977.0%   
Current liabilities Rs m3,5732 193,113.5%   
Net working cap to sales %148.2791.5 18.7%  
Current ratio x2.631.2 8.3%  
Inventory Days Days176741 23.8%  
Debtors Days Days37130,353,184 0.0%  
Net fixed assets Rs m2,48015 16,654.1%   
Share capital Rs m12340 308.6%   
"Free" reserves Rs m7,01831 22,660.6%   
Net worth Rs m7,14171 10,064.0%   
Long term debt Rs m00-   
Total assets Rs m11,70373 16,113.6%  
Interest coverage x6.2-17.1 -36.2%   
Debt to equity ratio x00-  
Sales to assets ratio x0.30.1 335.2%   
Return on assets %2.4-1.4 -170.5%  
Return on equity %2.9-1.6 -187.6%  
Return on capital %6.7-1.7 -396.4%  
Exports to sales %9.33.2 287.2%   
Imports to sales %02.8 0.0%   
Exports (fob) Rs m354NA 153,726.1%   
Imports (cif) Rs mNANA 0.0%   
Fx inflow Rs m3540 153,726.1%   
Fx outflow Rs m9740 487,130.0%   
Net fx Rs m-6210 -2,068,966.7%   
CASH FLOW
From Operations Rs m-692-17 4,064.0%  
From Investments Rs m95217 5,650.8%  
From Financial Activity Rs m-368NA 920,000.0%  
Net Cashflow Rs m-1090 47,173.9%  

Share Holding

Indian Promoters % 0.0 61.1 -  
Foreign collaborators % 70.7 0.0 -  
Indian inst/Mut Fund % 0.9 0.0 8,700.0%  
FIIs % 0.1 0.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 29.3 38.9 75.3%  
Shareholders   44,640 5,377 830.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NOVARTIS With:   HCL INFOSYS    MMTC    SUNDRAM FASTENERS    FUTURE CONSUMER    STC INDIA    



Today's Market

Sensex Sheds 581 Points, Nifty Ends Near 17,100; HCL Tech & Tech Mahindra Top Losers(Closing)

Indian share markets witnessed negative trading activity throughout the day today and ended on a weak note.

Related Views on News

Sun Pharma vs Dr Reddy's: Which is Better? (Views On News)

Dec 16, 2021

In an extremely competitive market, two pharma companies are competing against each other to grab the top spot.

5 Stocks to Watch Out for Amid the Omicron Outbreak (Views On News)

Dec 3, 2021

As the new variant of Covid-19 emerges, keep an eye on these stocks.

This Stock Just Made a Historical Debut on the Exchanges (Views On News)

Nov 15, 2021

Shares of the company listed at premium of 253% from its IPO price, the highest ever.

3 Indian Pharma Companies that are Investing Big Time for the Future (Views On News)

Nov 9, 2021

In 2021, R&D of pharma companies roared to life in a never-before-seen way.

Demerger of Financial & Pharma Businesses puts Piramal Enterprises in Limelight (Views On News)

Oct 8, 2021

The company's shareholders will be issued 4 shares in the demerged entity for every 1 held in Piramal Enterprises.

More Views on News

Most Popular

These 5 Penny Stocks are Held by Rakesh Jhunjhunwala. Worth a Look?(Views On News)

Jan 18, 2022

Rakesh Jhunjhunwala is holding these penny stocks in his portfolio for several years now.

Time to Buy Energy Stocks(Fast Profits Daily)

Jan 14, 2022

Energy is a sector that looks set to take off. It's time to get in.

Tech Mahindra's CTC Acquisition: Too Expensive?(Views On News)

Jan 18, 2022

Tech Mahindra's acquisition of European IT-company fails to excite investors.

5 Hidden Tata Group Companies to Add to Your Watchlist(Views On News)

Jan 18, 2022

Here's all you need to know about these five Tata group stocks that aren't as popular as the others.

Insiders are Buying into these 6 Stocks Aggressively. More Details here...(Views On News)

Jan 19, 2022

While promoter holding is an important parameter, it should not be the sole reason for buying a stock.

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Jan 27, 2022 (Close)

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE NOVARTIS WITH

MARKET STATS